CA2718463A1 - Novel uses for 4-phenylbutyrate (4pba) and its pharmaceutically acceptable salts - Google Patents

Novel uses for 4-phenylbutyrate (4pba) and its pharmaceutically acceptable salts Download PDF

Info

Publication number
CA2718463A1
CA2718463A1 CA2718463A CA2718463A CA2718463A1 CA 2718463 A1 CA2718463 A1 CA 2718463A1 CA 2718463 A CA2718463 A CA 2718463A CA 2718463 A CA2718463 A CA 2718463A CA 2718463 A1 CA2718463 A1 CA 2718463A1
Authority
CA
Canada
Prior art keywords
4pba
disease
alzheimer
treatment
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2718463A
Other languages
English (en)
French (fr)
Inventor
Diana Sara Frechilla Manso
Ana Maria Garcia Osta
Luis Alberto Perez Mediavilla
Ana Lourdes Ricobaraza Abarquero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Publication of CA2718463A1 publication Critical patent/CA2718463A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2718463A 2008-03-13 2009-03-06 Novel uses for 4-phenylbutyrate (4pba) and its pharmaceutically acceptable salts Abandoned CA2718463A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200800736A ES2332687B1 (es) 2008-03-13 2008-03-13 Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
ESP200800736 2008-03-13
PCT/ES2009/000121 WO2009112609A1 (es) 2008-03-13 2009-03-06 Nuevos usos del 4-fenilbutirato de sodio (4 pba) y sus sales farmacéuticamente aceptables

Publications (1)

Publication Number Publication Date
CA2718463A1 true CA2718463A1 (en) 2009-09-17

Family

ID=40691368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2718463A Abandoned CA2718463A1 (en) 2008-03-13 2009-03-06 Novel uses for 4-phenylbutyrate (4pba) and its pharmaceutically acceptable salts

Country Status (11)

Country Link
US (1) US20110027251A1 (https=)
EP (1) EP2272515A1 (https=)
JP (1) JP2011518119A (https=)
CN (1) CN102036665A (https=)
AU (1) AU2009224613A1 (https=)
BR (1) BRPI0909745A2 (https=)
CA (1) CA2718463A1 (https=)
ES (1) ES2332687B1 (https=)
MX (1) MX2010009933A (https=)
RU (1) RU2010138638A (https=)
WO (1) WO2009112609A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523795A (ja) * 2010-04-06 2013-06-17 バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー 植物のストレス耐性を増強させるための４−フェニル酪酸及び／又はその塩の使用
CN101973868B (zh) * 2010-11-12 2012-08-15 北京恒瑞康达医药科技发展有限公司 苯丁酸钠ⅰ型结晶及其制备方法
EP2599479A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-phenylbutyric acid for the treatment of alzheimer's disease
WO2013149091A1 (en) * 2012-03-29 2013-10-03 The Regents Of The University Of Colorado, A Body Corporate Composition and method for treating neurodegenerative disease
CN102757334B (zh) * 2012-07-30 2014-05-28 北京恒瑞康达医药科技发展有限公司 苯丁酸钠ⅱ型晶体及其制备方法
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
EP3019865A4 (en) * 2013-07-12 2017-04-05 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
WO2017151487A1 (en) * 2016-02-29 2017-09-08 Neurovation Labs, Inc. Detection of glua1 in brain to identify the presence of glua1 -mediated ptsd
KR20250150154A (ko) 2016-03-15 2025-10-17 에이서 테라퓨틱스 인크. 소듐 페닐부티레이트를 포함하는 맛우수한 조성물 및 그의 용도
JP6962572B2 (ja) * 2016-03-18 2021-11-05 学校法人同志社 ２，４−ジアミノフェノール誘導体、及び、タウ及び／又はアミロイドβの凝集阻害剤
JP2019214546A (ja) * 2018-06-11 2019-12-19 学校法人福岡大学 終末糖化産物生成抑制剤及び医薬組成物
JP2020083827A (ja) * 2018-11-27 2020-06-04 国立研究開発法人農業・食品産業技術総合研究機構 ケミカルシャペロンまたは神経細胞死の抑制剤
US20220119794A1 (en) * 2018-12-27 2022-04-21 Virginia Polytechnic Institute And State University Chemically programmed neutrophils and uses thereof
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
WO2022125425A1 (en) * 2020-12-07 2022-06-16 University Of Miami Method of treating polyamine imbalance-related disorders
CA3237768A1 (en) * 2021-11-08 2023-05-11 Amylyx Pharmaceuticals, Inc. Combination of turso and sodium phenyl butyrate for the treatment of neurodegenerative diseases
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
CN116099003A (zh) * 2022-11-28 2023-05-12 核工业总医院 内质网应激抑制剂在放射性认知功能障碍药物中的应用
EP4661859A1 (en) 2023-02-10 2025-12-17 Ludwig-Maximilians-Universität München, in Vertretung des Freistaates Bayern Oral phenylbutyrate for treatment of human 4-repeat tauopathies
CN117338763A (zh) * 2023-11-01 2024-01-05 重庆医科大学 丁酸钠在制备治疗帕金森病的药物中的应用及其治疗新靶标

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
AU720643B2 (en) * 1996-08-13 2000-06-08 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US6664297B1 (en) * 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
ES2310213T3 (es) * 2001-05-02 2009-01-01 The Regents Of The University Of California Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa.
JP2005525345A (ja) * 2002-02-15 2005-08-25 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｔｒｘ媒介性疾患を処置する方法
EP3560496A1 (en) * 2008-04-29 2019-10-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate

Also Published As

Publication number Publication date
EP2272515A1 (en) 2011-01-12
AU2009224613A1 (en) 2009-09-17
RU2010138638A (ru) 2012-04-20
ES2332687B1 (es) 2011-01-10
JP2011518119A (ja) 2011-06-23
BRPI0909745A2 (pt) 2019-09-24
WO2009112609A1 (es) 2009-09-17
MX2010009933A (es) 2010-12-06
US20110027251A1 (en) 2011-02-03
CN102036665A (zh) 2011-04-27
ES2332687A1 (es) 2010-02-10

Similar Documents

Publication Publication Date Title
EP2272515A1 (en) Novel uses of sodium 4-phenylbutyrate (4 pba) and the pharmaceutically acceptable salts thereof
JP7365426B2 (ja) 精神障害、行動障害、認知障害を処置するための医薬組成物及び方法
JP6093180B2 (ja) ヒストンアセチルトランスフェラーゼ活性化剤及びその使用
JP2016529274A (ja) 神経疾患の処置のためのトラセミド及びバクロフェンを含む組成物
Wang et al. Exendin‑4 antagonizes Aβ1‑42‑induced attenuation of spatial learning and memory ability
EP3962488A1 (en) A method of treating mental, behavioral, cognitive disorders
US20120316247A1 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
WO2019205748A1 (zh) 一种化合物在抑制A β蛋白聚积治疗老年痴呆方面的应用
KR20230013116A (ko) 신경보호 유도용 화합물 및 조성물
AU2024202516A1 (en) Pharmaceutical combination and its use for treating synucleinopathies
Mohan et al. Unveiling acid-sensing ion channels (ASICs) in neurodegeneration: implications for disease pathogenesis and therapeutic strategies
JP7249433B2 (ja) 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物
CA3099090A1 (en) Pharmaceutical combinations of zonisamide and praxipexole, and related methods, for treating synucleinopathies
AU2011249223B2 (en) Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration
CA3096453C (en) Pharmaceutical combination comprising fluoxetine and pramipexole and its use for treating synucleinopathies
US20160136229A1 (en) Materials for positive cathepsin b modulation and methods of use for treating mild cognitive impairment (mci), early dementia, a-synucleinopathy, traumatic brain injury, cardiomyopathy, eye disease and skin damage
JP2022517734A (ja) ドンペリドン抗神経変性剤の組み合わせと使用
CN120131965A (zh) Glp-1受体激动剂治疗阿尔茨海默病的用途
HK40060568A (en) Domperidone antineurodegenerative combinations and use
Nakajima et al. Effects of Nobiletin in Animal Models of Cognitive Impairment: Current Insights and Future Perspectives

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140306